Preliminary results of 60 Degrees Pharma’s phase II study of ARAKODA® (tafenoquine) for treatment of mild-moderate COVID-19 disease have been published in the peer-reviewed journal, New Microbes and New Infections. Data from the study demonstrate a numerical reduction in the proportion of patients not recovered on Day 14, and that the incidence of drug-related adverse events was low (8.4 percent) and mild. The study also showed that time to clinical recovery from COVID-19 symptoms was accelerated by about 2 – 2.5 days in the tafenoquine arm.
ARAKODA is an anti-malarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It has not been approved by the U.S. Food and Drug Administration (FDA) for use in COVID-19 disease and the safety and effectiveness of tafenoquine in this population have not yet been demonstrated.